A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaShifu Xiao, Raoli He, Lu‐Ning Wang et al.|Alzheimer s Research & Therapy|2021Cited by 200
Antimalarial Drug Artemisinin Extenuates Amyloidogenesis and Neuroinflammation in <scp>APP</scp>swe/<scp>PS</scp>1dE9 Transgenic Mice via Inhibition of Nuclear Factor‐κ<scp>B</scp> and <scp>NLRP</scp>3 Inflammasome ActivationJian‐Quan Shi, Haiqiang Zou, Xiu‐Lan Sun et al.|CNS Neuroscience & Therapeutics|2013Cited by 113
Chiral nanoparticle-remodeled gut microbiota alleviates neurodegeneration via the gut–brain axisXiao Guo, Liguang Xu, Chen Li et al.|Nature Aging|2023Cited by 103
Anti-Malarial Drug Artemisinin Extenuates Amyloidogenesis and Neuroinflammation in APPswe/PS1dE9 Transgenic Mice Via Inhibition of NF-κB and NLRP3 Inflammasome Activation (IN9-2.004)Jian‐Quan Shi, Xiu‐Lan Sun, Jun Xu et al.|Neurology|2013Cited by 0
Anti-Malarial Drug Artemisinin Extenuates Amyloidogenesis and Neuroinflammation in APPswe/PS1dE9 Transgenic Mice Via Inhibition of NF-κB and NLRP3 Inflammasome Activation (P01.020)Jian‐Quan Shi, Xiu‐Lan Sun, Jun Xu et al.|Neurology|2013Cited by 0